Opiant Pharmaceuticals Stock

Opiant Pharmaceuticals EBIT per Employee

Delisted

The EBIT per Employee of Opiant Pharmaceuticals (OPNT) as of Aug 26, 2026 is 245,538.10 USD. In the previous year, EBIT per Employee was -106,666.67 USD — a change of -330.19% (higher).

EBIT per Employee

245,538.10USD

YoY

-330.19%

Last updated:

EBIT per Employee of Opiant Pharmaceuticals is 2026 245,538.10 USD. EBIT per Employee of Opiant Pharmaceuticals was 2025 -106,666.67 USD. It decreases by -330.19% higher compared to the previous year.

The Opiant Pharmaceuticals EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2014
-328,571.43 USD
Jan 1, 2015
-368,571.43 USD
Jan 1, 2016
337,619.05 USD
Jan 1, 2017
73,333.33 USD
Jan 1, 2018
-1.01 M USD
Jan 1, 2019
519,523.81 USD
Jan 1, 2020
-106,666.67 USD
Jan 1, 2021
245,538.10 USD
The Opiant Pharmaceuticals EBIT per Employee history
YEAREBIT per EmployeeYoY
245,538.10USD-330.19%
-106,666.67USD-120.53%
519,523.81USD-151.49%
-1.01 MUSD-1,475.97%
73,333.33USD-78.28%
337,619.05USD-191.60%
-368,571.43USD+12.17%
-328,571.43USD
Access this data via the Eulerpool API

Opiant Pharmaceuticals Stock analysis

What does Opiant Pharmaceuticals do? Opiant Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of medications for the treatment of addiction disorders and acute medical needs. The company was founded in 2006 and is headquartered in Santa Monica, California. Since its inception, Opiant Pharmaceuticals Inc. has developed innovative drugs that can help mitigate the effects of addiction disorders and meet the demand for emergency medications. The company follows a clear business model based on the implementation of clinical trials and the commercialization of the resulting medications. One of Opiant Pharmaceuticals Inc.'s core areas is the development of medications that can be used in the context of opioid overdoses. One of the best-known products is Narcan Nasal Spray, an emergency medication that can be used in cases of opioid overdose. The product is fast, easy, and safe to use and has proven to be highly effective in practice. In addition to the development of medications for the treatment of opioid overdoses, Opiant Pharmaceuticals Inc. has also developed medications for the treatment of alcohol dependence. One of the best-known medications is Nalmefene, sold as Selincro in Europe and Canada. The medication is used in combination with behavioral counseling and has proven to be an effective treatment option for patients with alcohol dependence. Another division of Opiant Pharmaceuticals Inc. is the development of medications for acute medical needs. This includes medications such as Fentanyl Nasal Spray, which can be used for the treatment of acute pain. Another medication is the opioid analgesic Oxycodone combined with Naltrexone, which is used for the treatment of moderate to severe pain. In addition, Opiant Pharmaceuticals Inc. also has a wide range of products in the pipeline that are in various stages of development and clinical trials. These include medications for the treatment of methamphetamine and cocaine dependence, as well as for postoperative nausea and vomiting. The company actively invests in research and development and is constantly striving to develop innovative and effective medications that can help minimize the effects of addiction disorders and meet medical needs. Overall, Opiant Pharmaceuticals Inc. has established itself as a leading provider of medications for the treatment of addiction disorders. The company has an impressive track record in drug development and aims to offer effective treatment options to patients around the world. With a strong pipeline of products and a dedicated leadership team, Opiant Pharmaceuticals Inc. is well-positioned to continue growing in the coming years and establish itself as a leading provider of medications for the treatment of addiction disorders. Opiant Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Opiant Pharmaceuticals stock

EBIT per Employee of Opiant Pharmaceuticals is 245,538.10 USD in 2026.

EBIT per Employee of Opiant Pharmaceuticals changed from -106,666.67 USD to 245,538.10 USD, representing a -330.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Opiant Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Opiant Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

Workforce — Opiant Pharmaceuticals

All Key Metrics — Opiant Pharmaceuticals